RPRD Diagnostics announced a collaboration with Children’s Minnesota dedicated to implementing a pharmacogenomic testing process. … By implementing this process the aim is to ensure patients get the right medication at the right time, making care more precise and more affordable.

News and Press Releases
RPRD, Children’s Minnesota Ink PGx Partnership
Children’s Minnesota to use RPRD Diagnostics platform for precision medicine
Pre-emptive genotyping for pharmacogenomic risk – establishing a benchmark
Affymetrix-Ulrich Broeckel Interview ASHG 2016
Medical College of Wisconsin Spinout RPRD Aims to Advance Clinical Pharmacogenomics
New Company RPRD Seeking to Test DNA, Anticipate Reactions to Drugs
Thermo Fisher Scientific Enables Preemptive Pharmacogenomic Screening Research with New PharmacoScan Solution
To meet the growing demand for preemptive pharmacogenomic risk factor screening that may one day aid drug prescription practices, Thermo Fisher Scientific today introduced PharmacoScan Solution, a new microarray-based research tool that contains pharmacogenomic content with relevant markers involved in absorption, distribution, metabolism and excretion (ADME) pathways of commonly prescribed medicines.
RPRD Diagnostics Launches to Bring Comprehensive Pharmacogenetics Testing to Routine Clinical Practice
RPRD (Right Person Right Drug) Diagnostics today announced its founding as a spin-off from the Medical College of Wisconsin (MCW). As a precision medicine company, RPRD Diagnostics is focused on providing comprehensive pharmacogenetics testing services, which analyze patients’ genomes for variations that are known to impact drug safety and efficacy, in a CLIA-certified lab.